TACROLIMUS ORAL
Total Payments
$202,748
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $202,748 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $202,748 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Molecular markers to differentiate calcineurin inhibitor toxicity from immunological mechanisms associated with progression to kidney dysfunction in kidney transplant recipients | Astellas Pharma Global Development | $169,500 | 0 |
| Financial burden of CMV mismatch CMV Donor Recipient - in lung transplant recipients. | Astellas Pharma Global Development | $33,248 | 0 |
Top Doctors Receiving Payments for TACROLIMUS ORAL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Charlottesville, VA | $202,748 | 4 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $202,748
Product Information
- Type Drug
- Total Payments $202,748
- Total Doctors 0
- Transactions 4
About TACROLIMUS ORAL
TACROLIMUS ORAL is a drug associated with $202,748 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2018 to 2018. In 2018, $202,748 was paid across 4 transactions to 0 doctors.
The most common payment nature for TACROLIMUS ORAL is "Unspecified" ($202,748, 100.0% of total).
TACROLIMUS ORAL is associated with 2 research studies, including "Molecular markers to differentiate calcineurin inhibitor toxicity from immunological mechanisms associated with progression to kidney dysfunction in kidney transplant recipients" ($169,500).